641571-12-2

Basic information

• Product Name: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile
• Synonyms: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile;-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile;Nilotinib Impurity 12;Benzonitrile,3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)-
• CAS NO: 641571-12-2
• Molecular Formula: C₁₂H₈F₃N₃
• Molecular Weight: 0
• Product Categories: API intermediates
• Mol File: 641571-12-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(641571-12-2)
• EPA Substance Registry System: 3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile(641571-12-2)

Safety Data

• Hazardous Substances Data: 641571-12-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzonitrile is used as a reagent for the synthesis of small molecular inhibitors. These inhibitors are designed to target the catalytic domains of protein kinases that are not in an active conformation. By inhibiting these protein kinases, the compound can potentially play a role in the development of therapeutics for various diseases, including cancer and other conditions involving abnormal cell signaling.

Upstream product

• 693-98-1 2-methylimidazole 
• 149793-69-1 3-fluoro-5-trifluoromethyl-benzonitrile 
• 822-36-6 4-methyl-1H-imidazole 

Downstream Products

• 917391-28-7 3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzamide 
• 641571-13-3 3-(4-methyl-imidazol-1-yl)-5-trifluoromethylbenzoic acid 

Relevant articles and documents

PROTEIN KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

A type-ii kinase inhibitor capable of inhibiting the T315I "Gatekeeper" mutant of Bcr-Abl

The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I "gatekeeper" mutation. Here we describe a type-II T315I inhibitor 2 (GNF-7), based upon a 3,4-dihydr

AMINOPYRIMIDINE COMPOUNDS AND THEIR SALTS, PROCESS FOR PREPARATION AND PHARMACEUTICAL USE THEREOF

The present invention provides aminopyrimidine compounds of formula (I) and their salts, wherein R1, R2, R3, R4, R5, R6, Q, Z, L, m, n are defined as the description, the methods for preparation thereof, the uses thereof and the pharmaceutical compositions comprising the effective amount of compounds of formula (I). The compounds of formula (I) and their salts can be used as protein kinase inhibitors.

CHEMICAL COMPOUNDS

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, of the formula (I): which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

PROCESS FOR THE SYNTHESIS OF ORGANIC COMPOUNDS

The present invention provides an efficient, safe and cost effective way to prepare 5 (4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II).

INHIBITORS OF TYROSINE KINASES

The invention relates to compounds of formula (I) Wherein the substituents R1, R2 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, especially a neoplastic disease, in particular leukaemia, and a method for the treatment of such disease.

NOVEL PYRIMIDINEAMIDE DERIVATIVES AND THE USE THEREOF

The invention relates to novel substituted N-(3-benzoylaminophenyl)-4-pyridyl-2-pyrimidinarnine derivatives, processes for the preparation thereof, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more oth